Nucleic acid-controlled catalytic rnas for trigger-responsive regulation
US-2024425855-A1 · Dec 26, 2024 · US
US9556430B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9556430-B2 |
| Application number | US-91564506-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 30, 2006 |
| Priority date | May 27, 2005 |
| Publication date | Jan 31, 2017 |
| Grant date | Jan 31, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides a method of analyzing the methylation status of all or part of an entire genome. Moreover, the invention features methods of and reagents for characterizing biological cells containing DNA that is susceptible to methylation. Such methods include methods of diagnosing cancer, e.g., breast cancer.
Opening claim text (preview).
What is claimed is: 1. A method of determining, in a human test tissue fibroblast, the level of methylation of one methylation site in a region of the TMEM39A gene, the C7orf3 gene, or the IRX5 gene that is 5′ of the transcription start site, the method comprising determining the level of methylation of a methylation site in a section of a gene by experimentally assaying, in a test fibroblast from test breast tissue, the degree of methylation of a cytosine residue in a CpG sequence in the section of the gene, wherein (i) the gene is TMEM39A gene, the section of the gene is 5′ of the transcription start site of the gene, and the CpG sequence is in the AscI restriction site (A) that is in the region of the gene 5′ of the transcription start site of the gene and (B) that was identified by the Methylation Specific Digital Karyotyping (MSDK) tag consisting of SEQ ID NO:621; (ii) the gene is the C7orf3 gene, the section of the gene is 5′ of the transcription start site of the gene, and the CpG sequence is in the AscI restriction site (A) that is in the region of the gene 5′ of the transcription start site of the gene and (B) that was identified by the MSDK tag consisting of SEQ ID NO:731; or (iii) the gene is the IRX5 gene, the section of the gene is 5′ of the transcription start site of the gene, and the CpG sequence is in the AscI restriction site (A) that is in the region of the gene 5′ of the transcription start site of the gene and (B) that was identified by the MSDK tag consisting of SEQ ID NO:904. 2. The method of claim 1 , wherein the gene is the TMEM39A gene. 3. The method of claim 1 , wherein the gene is the C7orf3 gene. 4. The method of claim 1 , wherein the gene is the IRX5 gene.
Ligating adaptors · CPC title
Methylation site specific nuclease · CPC title
Expression markers · CPC title
General methods of preparing gene libraries, not provided for in other subgroups · CPC title
Methylation markers · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.